Dendrite International, Inc. Announces Appointment of Marc Kustoff to Chief Technology Officer.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Nov. 21, 2000

Dendrite International, Inc., the leading provider of sales and marketing effectiveness solutions for the pharmaceutical industry (NASDAQ/NMS:DRTE), recently announced the appointment of Marc Kustoff to the position of Senior Vice President and Chief Technology Officer, reporting to John Bailye.

Marc brings more than 16 years of experience in Information Systems management to Dendrite, with an extensive focus on the pharmaceutical industry. "In his newly created role as Chief Technology Officer, Marc Kustoff will be instrumental in shaping Dendrite's technology vision and will provide a knowledgeable link between pharmaceutical companies' sales representatives and their key customer audiences," comments John Bailye, Chairman and Chief Executive Officer of Dendrite International. "We are pleased that our expansion plans are progressing well and that our efforts to secure talented senior executives to drive Dendrite's strategic initiatives have been so successful."

"The pharmaceutical marketplace is always evolving, and companies that serve this industry must constantly provide new products and services based on the latest technology," said Kustoff. "With its unique data and powerful analytic capabilities, Dendrite has poised itself at the forefront of this industry by remaining dedicated to offering pharmaceutical sales representatives the most advanced support tools available. I am excited about being part of a dynamic organization that prides itself on being a leader within the pharmaceutical industry and look forward to being a part of the Company's future, technology-driven initiatives."

Prior to joining Dendrite, Kustoff served as Vice President, Information Systems at Parke-Davis Pharmaceutical Co., located in Morris Plains, NJ, where he played a vital role in leading the company's Information Technologies strategies during a period of explosive business growth. In addition, Kustoff also has held key management positions at Corning Life Sciences, Inc. and Rhone-Poulenc Rorer, Inc.

ABOUT DENDRITE

Dendrite International, Inc. (NASDAQ/NMS:DRTE) designs and supports technology-based knowledge systems that enhance the competitive activities of the sales forces of the world's largest pharmaceutical companies. Over one-third of the pharmaceutical sales representatives and their managers in over 57 countries worldwide rely on Dendrite to provide these services to maximize representative effectiveness in the field. Dendrite combines its world-class software products with specifically tailored coaching and support services. Headquartered in Morristown, New Jersey, Dendrite employs over 1500 people around the world. For more information, visit the Company's Web site at http://www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc. * advanced software and tools, and valuable services

This press release contains forward-looking statements that discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) timing of revenue recognition is dependent of many factors including timing of customer acceptance of product offerings and execution of contracts for Dendrite products, which factors are often outside the Company's control and which cannot always be predicted;(ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be able to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.